Scpharmaceuticals INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$2.8Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
16,091clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2023 $608K
2024 $927K
2025 $1.2M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Cardiovascular Disease $1.1M
Advanced Heart Failure and Transplant Cardiology $546K
Nephrology (Internal Medicine) $201K
Interventional Cardiology $171K
Family $162K
Nurse Practitioner $108K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Hunter Champion Columbus, GA Cardiovascular Disease $174,752.56
William Abraham Columbus, OH Advanced Heart Failure and Transplant Cardiology $133,127.44
Daniel Bensimhon Greensboro, NC Advanced Heart Failure and Transplant Cardiology $105,372.76
Georges Chahoud Saint Louis, MO Cardiovascular Disease $71,747.84
Vamsi Krishna Kyle, TX Interventional Cardiology $67,248.38
Gautam Shah Fairview Park, OH Cardiovascular Disease $64,263.05
Benjamin Kalsmith Pgh, PA Cardiovascular Disease $62,915.96
Erika Feller Baltimore, MD Cardiovascular Disease $61,016.99
Rigved Tadwalkar Santa Monica, CA Cardiovascular Disease $58,750.13
Amin Yehya Norfolk, VA Advanced Heart Failure and Transplant Cardiology $53,786.20

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.